Phio Pharmaceuticals Corp. Common Stock
PHIOStock
$1.00−62.60%52W
Market Cap$10.37M
P/E—
Div yield—
Beta0.79
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-35.90%
Price vs S&P 500 (4W)-16.63%
VGM Score31.17
Market Capitalization$10.37M
Earnings Surprise History
Q1 26-0.34est. -0.24
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PHIOPhio Pharmaceuticals Corp. Common Stock | — | — | D | $1.00 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Phio Pharmaceuticals is a clinical-stage biopharmaceutical company developing cancer immunotherapies using its proprietary INTASYL RNA gene silencing technology to enhance immune cells' ability to kill tumor cells. The platform precisely targets proteins that suppress anti-cancer immunity without requiring specialized drug delivery systems. The company's pipeline includes candidates PH-762 and PH-894, with all operations based in the United States.